Additional file 3 of Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma

Additional file 3: Figure S1 Performance comparison between the copy number profile abnormality (CPA) score and previously published alternatives, applied to all liquid biopsies. Figure S2 Tumor heterogeneity analysis, applied to patients with a liquid (LB) and solid biopsy (SB) taken no longer than 50 days apart. Figure S3 Cluster analysis, applied to all liquid biopsies. Figure S4 Prediction accuracy in relation to abnormality cutoff stringency. Figure S5 Performance of predicting histology by single-end (SE) versus paired-end (PE) sequencing. Figure S6 Copy number profiles of a relapsed patient with small cell transformation/a second primary tumor.